ORLYNVAH is a combination of sulopenem etzadroxil (a penem antibiotic drug) and probenecid (a kidney transport blocking drug) that is indicated for the treatment of uncomplicated urinary tract infections (uUTI) caused by the bacteria Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult female patients who have limited or no alternative oral antibiotic treatment options.
https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-orlynvah
No hay comentarios:
Publicar un comentario